SRX vs BTG, page-10

'SRX should see a boost to Revenue, EPS of ~25% compared to last year as per their own forward guidance.'

Tim, I'm not sure srx has given any guidance for dose sales, revenue, or profits.

However I would tend to concur that a 25% increase in EPs could be expected, based on the expected dose increase. The $1k price increase in the US should add another few % points to the profit number, but may be more marginal at the EPs level.

The $AU situation gets interesting. In April this year it was about 94c, and currently about 81c. Around a 15% fall. According to the eoy report this is worth $15m on the bottom line. One would have to calculate the weighted average during the full fiscal year to start any serious analysis, but at the simplistic level I think the current situation is about 10%+ against the average for last year.

I can see sales revenue for the current 6 months being north of $86m. What this does to the bottom line probably more variable as they are ramping up sales and marketing spend in a big way, IMO.

Last year's sales revenue was $129, at the simplistic level $65m for the half year. Add in 28% dose sales growth = $83m, than add 6.7% for US price increase = $87m (allowing for about 80% sales being sourced in the US). Then add some au$ benefit, say 10%, and mid 90s is not beyond belief.

I'll leave to others to estimate the bottom line, but 25% increase in EPS should not be too difficult, IMO.